Core Viewpoint - The company, Boji Pharmaceutical, emphasizes its competitive edge in traditional Chinese medicine (TCM) research and development services, focusing on providing comprehensive TCM R&D services and enhancing its capabilities in the field [1] Group 1: Business Focus - The company primarily offers TCM R&D services through its wholly-owned subsidiary, Xinglin TCM, which provides clinical, preclinical, and registration services for TCM [1] - The company’s controlling subsidiary, Henan Kangli, specializes in post-marketing re-evaluation services for TCM [1] Group 2: Research and Development Achievements - In the past two years, the company has successfully developed TCM Class 1.2 CRA (raw materials and formulations) and Class 1.1 Qingzhi ointment, both of which have received the "Drug Clinical Trial Approval Notice" [1] - Several innovative TCM self-research projects are currently in the preclinical development stage [1] Group 3: Future Strategy - The company plans to continue prioritizing TCM R&D services while supplementing its self-research efforts and aims to attract more TCM R&D talent to enhance its competitiveness in the TCM sector [1]

Investment Rating - The report maintains a "Strong Buy" rating for Yangnong Chemical [2][5] Core Views - Yangnong Chemical reported a revenue of 3.241 billion yuan in Q1 2025, a year-on-year increase of 2.04%, with a net profit of 435 million yuan, up 1.35% year-on-year. The growth was driven by an increase in pesticide sales despite a slight decline in prices [3] - The company is progressing steadily with new project capacity construction, which is expected to contribute to performance growth in the future. By the end of 2024, the cumulative investment in the Liaoning Youchuang Phase I project will reach 2.783 billion yuan, accounting for 80% of the total budget [5] - The agricultural chemical industry is currently at the bottom of the cycle, but opportunities are emerging from green development, internationalization, and increased industry concentration. The demand for agricultural products is expected to rise in the long term, supported by favorable policies and increased planting areas in major producing countries [4] Financial Performance Summary - In Q1 2025, the raw material segment saw a price decline of 8.77% year-on-year, but sales volume increased by 14.82%, leading to a revenue increase of 4.75% to 1.806 billion yuan. The formulation segment experienced a price drop of 1.63% year-on-year, with a sales volume increase of 2.77%, resulting in a revenue increase of 1.10% to 871 million yuan [3] - The comprehensive gross profit margin increased by 0.3 percentage points year-on-year to 24.64%, contributing to the growth in net profit [3] - The financial forecast for 2025-2027 estimates net profits of 1.355 billion, 1.643 billion, and 2.095 billion yuan, respectively, with corresponding EPS of 3.33, 4.04, and 5.15 yuan, and current P/E ratios of 16, 13, and 10 times [5][6]

Investment Rating - The report maintains a "Strong Buy" rating for Yangnong Chemical [2][5]. Core Insights - Yangnong Chemical reported a revenue of 3.241 billion yuan in Q1 2025, a year-on-year increase of 2.04%, with a net profit of 435 million yuan, up 1.35% year-on-year. The growth was driven by an increase in pesticide sales despite a slight decline in prices [3]. - The company is progressing steadily with new project capacity construction, which is expected to contribute to performance growth in the future. By the end of 2024, the cumulative investment in the Liaoning Youchuang Phase I project will reach 2.783 billion yuan, accounting for 80% of the total budget [5]. - The agricultural chemical industry is currently at the bottom of the cycle, but opportunities are emerging due to green development, internationalization, and increased industry concentration. The demand for agricultural products is expected to remain stable in the long term, supported by favorable government policies and the expansion of planting areas in major grain-producing countries [4]. Financial Performance Summary - In Q1 2025, the revenue from raw materials increased by 4.75% to 1.806 billion yuan, while the revenue from formulations grew by 1.10% to 871 million yuan. The overall gross margin increased by 0.3 percentage points to 24.64% [3]. - The financial forecast for Yangnong Chemical estimates net profits of 1.355 billion yuan, 1.643 billion yuan, and 2.095 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.33 yuan, 4.04 yuan, and 5.15 yuan [5][6].